Clinical Infectious Diseases Review Time

CID's official pages now do two things unusually well. First, the author guidance says the journal aims to make desk rejection decisions within one week of submission. Second, the "Why Publish" page shows medians both with and without desk rejects included.

That distinction matters a lot. It tells you the journal is not hiding the ball. The better planning model is:

• expect a fast answer if the paper is not clinically right for CID
• expect roughly five to six weeks to first decision if the paper enters full review
• expect about two to two-and-a-half months to final decision on reviewed manuscripts

The official split is much more useful than anecdotal forum posts.

That is the cleanest way to think about CID. It is not a universally fast journal. It is a journal with a very efficient front-end filter.

CID has a sharp clinical identity. It wants studies that change diagnosis, treatment, prevention, or patient management. That makes early filtering easier than at many journals.

Editors can reject quickly when a manuscript is:

• largely microbiology without patient outcomes
• underpowered for its stated clinical endpoint
• describing an interesting pathogen or resistance mechanism without bedside consequence
• clinically relevant only in a very narrow local way
• using observational data to make stronger treatment claims than the design supports

The one-week desk target and the 6-day first-decision median are both easy to understand once that editorial filter is clear.

The slower papers are usually not obviously wrong for the journal. They are the ones where the clinical message is plausible but still contestable.

The common causes are:

• reviewer disagreement about whether the result really changes practice
• cohort size or follow-up questions that weaken confidence in the main endpoint
• studies that bridge clinical infectious disease and microbiology awkwardly
• revision requests around generalizability, stewardship implications, or causal overreach
• outbreak or epidemiology papers whose immediate relevance is less obvious outside one setting

When CID feels slow, it is often because the editors and reviewers are testing whether the study earns the phrase "clinically useful" rather than merely sounding clinically adjacent.

Clinical Infectious Diseases is down from 11.8 in 2023 to 7.3 in 2024, which is best read as post-pandemic normalization rather than editorial decline. The 5-year JIF of 7.2 and the journal's still-large citation footprint suggest a stable post-spike baseline.

For review time, that stability helps explain why the journal can keep triaging hard. CID does not need to widen its scope to preserve relevance. It can keep deciding quickly whether the paper will matter to practicing infectious disease readers.

Even with this unusually good official dashboard, a few things stay hidden:

• desk rejections dramatically compress the all-submission medians
• a paper can reach first decision in 39 days and still face a major revision
• the "without desk rejects" number still masks big differences by article type
• timing does not tell you whether the paper is too descriptive, too local, or too weakly practice-facing

So the numbers are excellent planning tools, but they are not substitutes for scope discipline.

In our pre-submission review work, the biggest timing mistake is sending a paper that is clinically adjacent rather than clinically decisive. CID editors usually identify that immediately.

The files that move most cleanly through CID tend to have:

• patient outcomes or clinical management consequence visible in the abstract
• a cohort large enough for the claimed endpoint
• conclusions disciplined to the limits of the design
• clear relevance to diagnosis, treatment, prevention, stewardship, or management

Those are the traits that use CID's fast front end well. Otherwise the speed mostly becomes a fast rejection signal.

For CID, timing matters less than clinical utility. The better question is whether the manuscript already behaves like a Clinical Infectious Diseases paper.

That is why the better next reads are:

• Clinical Infectious Diseases journal profile
• Clinical Infectious Diseases submission guide
• Clinical Infectious Diseases impact factor
• Clinical Infectious Diseases acceptance rate

A CID clinical-utility check is usually higher leverage than trying to optimize around review speed alone.

Clinical Infectious Diseases review time is a strong example of why journals should separate desk-reject medians from reviewed-paper medians. CID does, and the result is actually useful. The journal is fast to decide whether the paper belongs, then more normally paced once the paper earns peer review.